Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma (NCT07218315) | Clinical Trial Compass
RecruitingNot Applicable
Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma
United States15 participantsStarted 2026-02-11
Plain-language summary
This study is to evaluate the effectiveness of nsPFA in treating papillary thyroid microcarcinoma. T
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Participant must provide voluntary, written informed consent to participate in this clinical investigation.
* Participant agrees to comply with all study procedures, including all follow-up visits.
* Participant with a Bethesda VI cytology (tumor size \<= 1.5 cm, no known regional/distant metastases)
* Participant with a Bethesda V cytology and normal calcitonin levels.
* Ultrasonographic evaluation of tumor to be ablated must show size of less than or equal to 1.5 cm and no extrathyroidal extension or locoregional metastases.
* Participant must have normal complete blood count, blood coagulation profile, and thyroid function test.
* For females of childbearing potential, a negative serum or urine pregnancy test must be obtained at baseline, prior to the procedure.
* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following: ). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the foll…
What they're measuring
1
Safety and Adverse Events (AEs)
Timeframe: Through study completion; an average of 1 year